Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Trastuzumab deruxtecan shows encouraging overall response rates in untreated HER2-positive metastatic breast cancer
Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
An analysis reveals distinct patterns of expression of antibody–drug conjugate targets in high-grade serous ovarian cancer